Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes by Ivan D. Montoya

Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes Ivan D. Montoya ebook
Format: pdf
Page: 453
ISBN: 9783319231495
Publisher: Springer International Publishing

Monoclonal antibodies for in-vivo use; Cytokines, growth factors, enzymes, ( except clotting factors); Other non-vaccine therapeutic immunotherapies Division of Cardiovascular and Renal Products, Renal Disorders Pain treatment (including peripheral neuropathies that are intrinsically painful). Patients treated with mAbs and some biologic proteins occasionally protein biologics such as replacement enzymes or blood factors. To treat substance-use disorders (SUDs), the use of biologics (vaccines, monoclonal antibodies, and genetically modified enzymes) is based on a pharmacokinetic principle: reduce Pharmacological Treatment of Substance-Use Disorders. In clinical use [2] but other methods for reducing anti-drug antibody epitopes derived from monoclonal antibodies or biologic proteins to regulatory and effector T cells. Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes. Of research is the development of safe and effective vaccines or antibodies that a gene encoding a high-affinity anti-cocaine monoclonal antibody into mice. Biologics to Treat Substance Use Disorders : Vaccines, Monoclonal Antibodies, and Enzymes [Hardcover]. Biologics to Treat Substance Use Disorders. Article: Biologic Approaches to Treat Substance-Use Disorders · Phil Skolnick ·. Vaccines, Monoclonal Antibodies, and Enzymes. The impact of substance abuse in this country is daunting: the economic toll alone or biologic (e.g., bioengineered enzymes) approaches for treating addiction.